Literature DB >> 23356300

The role of microvesicles in cancer progression and drug resistance.

Samireh Jorfi1, Jameel M Inal.   

Abstract

Microvesicles are shed constitutively, or upon activation, from both normal and malignant cells. The process is dependent on an increase in cytosolic Ca2+, which activates different enzymes, resulting in depolymerization of the actin cytoskeleton and release of the vesicles. Drug resistance can be defined as the ability of cancer cells to survive exposure to a wide range of anti-cancer drugs, and anti-tumour chemotherapeutic treatments are often impaired by innate or acquired MDR (multidrug resistance). Microvesicles released upon chemotherapeutic agents prevent the drugs from reaching their targets and also mediate intercellular transport of MDR proteins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23356300     DOI: 10.1042/BST20120273

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  18 in total

Review 1.  Extracellular vesicles in breast cancer drug resistance and their clinical application.

Authors:  Shentong Yu; Yifang Wei; Yuqiao Xu; Yuan Zhang; Jipeng Li; Jian Zhang
Journal:  Tumour Biol       Date:  2016-01-21

2.  BCR-ABL1-positive microvesicles transform normal hematopoietic transplants through genomic instability: implications for donor cell leukemia.

Authors:  X Zhu; Y You; Q Li; C Zeng; F Fu; A Guo; H Zhang; P Zou; Z Zhong; H Wang; Y Wu; Q Li; F Kong; Z Chen
Journal:  Leukemia       Date:  2014-01-31       Impact factor: 11.528

Review 3.  Tumor-derived extracellular vesicles: Potential tool for cancer diagnosis, prognosis, and therapy.

Authors:  Tayyaba Saleem; Aleena Sumrin; Muhammad Bilal; Hamid Bashir; Muhammad Babar Khawar
Journal:  Saudi J Biol Sci       Date:  2022-01-12       Impact factor: 4.052

4.  Extracellular vesicles: potential applications in cancer diagnosis, prognosis, and epidemiology.

Authors:  Mukesh Verma; Tram Kim Lam; Elizabeth Hebert; Rao L Divi
Journal:  BMC Clin Pathol       Date:  2015-04-15

5.  A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy.

Authors:  Sharad Kholia; Samireh Jorfi; Paul R Thompson; Corey P Causey; Anthony P Nicholas; Jameel M Inal; Sigrun Lange
Journal:  J Extracell Vesicles       Date:  2015-06-19

6.  Isolation, characterization and potential role in beta cell-endothelium cross-talk of extracellular vesicles released from human pancreatic islets.

Authors:  Federico Figliolini; Vincenzo Cantaluppi; Michela De Lena; Silvia Beltramo; Renato Romagnoli; Mauro Salizzoni; Raffaella Melzi; Rita Nano; Lorenzo Piemonti; Ciro Tetta; Luigi Biancone; Giovanni Camussi
Journal:  PLoS One       Date:  2014-07-16       Impact factor: 3.240

7.  Comparison of microRNA expression profiles in K562-cells-derived microvesicles and parental cells, and analysis of their roles in leukemia.

Authors:  Xiaomei Chen; Wei Xiong; Huiyu Li
Journal:  Oncol Lett       Date:  2016-10-24       Impact factor: 2.967

8.  Saline is a more appropriate solution for microvesicles for flow cytometric analyses.

Authors:  Xing Xin; Peiling Zhang; Xing Fu; Xia Mao; Fankai Meng; Ming Tian; Xiaojian Zhu; Hanying Sun; Li Meng; Jianfeng Zhou
Journal:  Oncotarget       Date:  2017-05-23

Review 9.  Peptidylarginine Deiminases-Roles in Cancer and Neurodegeneration and Possible Avenues for Therapeutic Intervention via Modulation of Exosome and Microvesicle (EMV) Release?

Authors:  Sigrun Lange; Mark Gallagher; Sharad Kholia; Uchini S Kosgodage; Mariya Hristova; John Hardy; Jameel M Inal
Journal:  Int J Mol Sci       Date:  2017-06-05       Impact factor: 5.923

10.  Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo.

Authors:  Samireh Jorfi; Ephraim A Ansa-Addo; Sharad Kholia; Dan Stratton; Shaunelle Valley; Sigrun Lange; Jameel Inal
Journal:  Sci Rep       Date:  2015-08-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.